Edward V. Lis

1.4k total citations
22 papers, 1.1k citations indexed

About

Edward V. Lis is a scholar working on Social Psychology, Molecular Biology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Edward V. Lis has authored 22 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Social Psychology, 8 papers in Molecular Biology and 7 papers in Cellular and Molecular Neuroscience. Recurrent topics in Edward V. Lis's work include Neuroendocrine regulation and behavior (11 papers), Receptor Mechanisms and Signaling (5 papers) and Organic and Inorganic Chemical Reactions (5 papers). Edward V. Lis is often cited by papers focused on Neuroendocrine regulation and behavior (11 papers), Receptor Mechanisms and Signaling (5 papers) and Organic and Inorganic Chemical Reactions (5 papers). Edward V. Lis collaborates with scholars based in United States. Edward V. Lis's co-authors include Douglas J. Pettibone, Bradley V. Clineschmidt, Kathryn Jones, David L. Williams, Duane R. Reiss, Anthony G. DiLella, Marion Wittmann, Michael J. Marino, P. Jeffrey Conn and Gene G. Kinney and has published in prestigious journals such as Journal of Neuroscience, Biochemical and Biophysical Research Communications and Journal of Medicinal Chemistry.

In The Last Decade

Edward V. Lis

22 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Edward V. Lis United States 14 516 414 406 222 154 22 1.1k
Hélène Beaudry Canada 15 442 0.9× 402 1.0× 323 0.8× 269 1.2× 41 0.3× 27 926
V. Daugé France 15 648 1.3× 844 2.0× 333 0.8× 108 0.5× 60 0.4× 25 1.4k
James A. Weyhenmeyer United States 23 707 1.4× 634 1.5× 207 0.5× 427 1.9× 127 0.8× 52 1.5k
Michael DePasquale United States 17 393 0.8× 343 0.8× 102 0.3× 153 0.7× 44 0.3× 32 1.0k
Duane R. Reiss United States 20 361 0.7× 257 0.6× 88 0.2× 47 0.2× 148 1.0× 34 1.3k
Joel R. Gever United States 20 684 1.3× 302 0.7× 282 0.7× 68 0.3× 64 0.4× 33 1.6k
Timothy Angelotti United States 14 509 1.0× 449 1.1× 235 0.6× 75 0.3× 16 0.1× 34 1.1k
John Lesnick United States 9 530 1.0× 330 0.8× 151 0.4× 44 0.2× 46 0.3× 12 846
Shaun Gorman United Kingdom 5 696 1.3× 401 1.0× 582 1.4× 119 0.5× 18 0.1× 7 1.1k
Tomio Andoh Japan 17 414 0.8× 240 0.6× 77 0.2× 96 0.4× 25 0.2× 71 1.1k

Countries citing papers authored by Edward V. Lis

Since Specialization
Citations

This map shows the geographic impact of Edward V. Lis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward V. Lis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward V. Lis more than expected).

Fields of papers citing papers by Edward V. Lis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward V. Lis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward V. Lis. The network helps show where Edward V. Lis may publish in the future.

Co-authorship network of co-authors of Edward V. Lis

This figure shows the co-authorship network connecting the top 25 collaborators of Edward V. Lis. A scholar is included among the top collaborators of Edward V. Lis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward V. Lis. Edward V. Lis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zeng, Haoyu, María I. Román, Edward V. Lis, Armando Lagrutta, & Frederick Sannajust. (2016). Use of FDSS/μCell imaging platform for preclinical cardiac electrophysiology safety screening of compounds in human induced pluripotent stem cell-derived cardiomyocytes. Journal of Pharmacological and Toxicological Methods. 81. 217–222. 29 indexed citations
2.
Zhang, Xiaoyu, Liang Guo, Haoyu Zeng, et al.. (2016). Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment. Journal of Pharmacological and Toxicological Methods. 81. 201–216. 57 indexed citations
3.
Lagrutta, Armando, Haoyu Zeng, John P. Imredy, et al.. (2016). Interaction between amiodarone and hepatitis-C virus nucleotide inhibitors in human induced pluripotent stem cell-derived cardiomyocytes and HEK-293 Cav 1.2 over-expressing cells. Toxicology and Applied Pharmacology. 308. 66–76. 17 indexed citations
4.
Smith, Karen, Susan Browne, Srinivasan Jayaraman, et al.. (2014). Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice. European Journal of Pharmacology. 728. 31–38. 10 indexed citations
5.
DiLella, Anthony G., et al.. (2010). Molecular Profiling of a 6-Hydroxydopamine Model of Parkinson’s Disease. Neurochemical Research. 35(5). 761–772. 41 indexed citations
6.
Hess, J. Fred, Richard W. Ransom, Zhizhen Zeng, et al.. (2004). Generation and Characterization of a Human Bradykinin Receptor B1 Transgenic Rat as a Pharmacodynamic Model. Journal of Pharmacology and Experimental Therapeutics. 310(2). 488–497. 19 indexed citations
7.
Valenti, Ornella, Michael J. Marino, Marion Wittmann, et al.. (2003). Group III Metabotropic Glutamate Receptor-Mediated Modulation of the Striatopallidal Synapse. Journal of Neuroscience. 23(18). 7218–7226. 140 indexed citations
8.
Pettibone, Douglas J., J. Fred Hess, Patricia J. Hey, et al.. (2002). The Effects of Deleting the Mouse Neurotensin Receptor NTR1 on Central and Peripheral Responses to Neurotensin. Journal of Pharmacology and Experimental Therapeutics. 300(1). 305–313. 111 indexed citations
9.
Williams, Peter D., Mark G. Bock, B. Evans, et al.. (1999). Nonpeptide oxytocin antagonists: Analogs of L-371,257 with improved potency. Bioorganic & Medicinal Chemistry Letters. 9(9). 1311–1316. 13 indexed citations
10.
Bock, Mark G., Roger Freidinger, Edward V. Lis, et al.. (1998). Nonpeptide oxytocin antagonists: Potent, orally bioavailable analogs of L-371,257 containing A 1-R-(pyridyl)ethyl ether terminus. Bioorganic & Medicinal Chemistry Letters. 8(21). 3081–3086. 9 indexed citations
11.
Williams, David L., Julie A. O’Brien, Edward V. Lis, et al.. (1996). Pharmacology of L-744,453, a novel nonpeptidyl endothelin antagonist. Life Sciences. 58(14). 1149–1157. 6 indexed citations
12.
13.
Williams, Paul, Bradley V. Clineschmidt, Jill M. Erb, et al.. (1995). 1-[1-[4-[(N-Acetyl-4-piperidinyl)oxy]-2- methoxybenzoyl]piperidin-4-yl]-4H-3,1- benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.. Journal of Medicinal Chemistry. 38(23). 4634–4636. 51 indexed citations
14.
Pettibone, Douglas J., Bradley V. Clineschmidt, Edward V. Lis, et al.. (1993). Identification of an orally active, nonpeptidyl oxytocin antagonist.. Journal of Pharmacology and Experimental Therapeutics. 264(1). 308–314. 22 indexed citations
15.
Williams, David L., Kathryn Jones, Douglas J. Pettibone, Edward V. Lis, & Bradley V. Clineschmidt. (1991). Sarafotoxin S6c: An agonist which distinguishes between endothelin receptor subtypes. Biochemical and Biophysical Research Communications. 175(2). 556–561. 339 indexed citations
16.
Pettibone, Douglas J., Bradley V. Clineschmidt, Edward V. Lis, et al.. (1991). Bradykinin agonist activity of a novel, potent oxytocin antagonist. European Journal of Pharmacology. 196(3). 233–237. 4 indexed citations
17.
Clineschmidt, Bradley V., Douglas J. Pettibone, Duane R. Reiss, et al.. (1990). Antagonism of oxytocin in rats and pregnant rhesus monkeys by the novel cyclic hexapeptides, L-366,682 and L-366,948.. Journal of Pharmacology and Experimental Therapeutics. 256(3). 827–832. 9 indexed citations
18.
Pettibone, Douglas J., Bradley V. Clineschmidt, Edward V. Lis, et al.. (1990). In vitro pharmacological profile of a novel structural class of oxytocin antagonists.. Journal of Pharmacology and Experimental Therapeutics. 256(1). 304–308. 18 indexed citations
19.
Clineschmidt, Bradley V., Douglas J. Pettibone, Victor J. Lotti, et al.. (1988). A peripherally acting alpha-2 adrenoceptor antagonist: L-659,066.. Journal of Pharmacology and Experimental Therapeutics. 245(1). 32–40. 110 indexed citations
20.
Clineschmidt, Bradley V. & Edward V. Lis. (1986). Pharmacological evaluation of d(CH2)5Tyr(Me)AVP as an antagonist of vasopressin-induced contraction of the isolated rat caudal artery.. PubMed. 284(1). 72–84. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hélène Beaudry Breakdown of academic impact, for papers by V. Daugé Breakdown of academic impact, for papers by James A. Weyhenmeyer Breakdown of academic impact, for papers by Michael DePasquale Breakdown of academic impact, for papers by Duane R. Reiss Breakdown of academic impact, for papers by Joel R. Gever Breakdown of academic impact, for papers by Timothy Angelotti Breakdown of academic impact, for papers by John Lesnick Breakdown of academic impact, for papers by Shaun Gorman Breakdown of academic impact, for papers by Tomio Andoh
Rankless by CCL
2026